Related Experiment Video
Updated: Jun 12, 2026
Production, Crystallization, and Structure Determination of the IKK-binding Domain of NEMO
Published on: December 28, 2019
A homogeneous time-resolved fluorescence-based high-throughput screening system for discovery of inhibitors of
Yusuke Gotoh1, Hidetaka Nagata, Hideo Kase
1Genomic Science Laboratories, Dainippon Sumitomo Pharma, Konohana-ku, Osaka 554-0022, Japan.
Insights
Researchers developed novel assays to find small molecules inhibiting the IKKbeta-NEMO interaction, crucial for inflammatory diseases like rheumatoid arthritis. Seven promising compounds were identified, offering potential new treatments for autoimmune disorders.
Area of Science:
- Biochemistry
- Immunology
- Pharmacology
Background:
- Nuclear transcription factor NF-kappaB regulates inflammatory and autoimmune responses.
- The IKK complex is central to NF-kappaB activation.
- Inhibiting the NEMO-IKKbeta interaction is a therapeutic target for inflammatory disorders.
Purpose of the Study:
- To develop and validate novel binding assays for identifying small molecules targeting the IKKbeta-NEMO interaction.
- To screen a chemical library for inhibitors of IKKbeta-NEMO binding.
- To identify potential therapeutic agents for inflammatory and autoimmune diseases.
Main Methods:
- Development of homogeneous time-resolved fluorescence (HTRF) and enzyme-linked immunosorbent assay (ELISA)-based assays.
- Screening of approximately 15,000 compounds using the HTRF assay.
- Validation of hits using ELISA and IKK complex kinase assays.
Main Results:
- Two novel binding assays (HTRF and ELISA) were successfully developed and validated.
- Approximately 15,000 compounds were screened, identifying seven positive hits.
- The identified compounds inhibit IKK complex activity by blocking the IKKbeta-NEMO interaction.
Conclusions:
- Novel HTRF and ELISA assays are effective for discovering small molecule inhibitors of IKKbeta-NEMO interaction.
- Seven hit compounds demonstrate potential for treating inflammatory and autoimmune disorders.
- Targeting the IKKbeta-NEMO interaction offers a promising therapeutic strategy for rheumatoid arthritis and similar conditions.
Abstract:
The nuclear transcription factor NF-kappaB is crucial to the expression of numerous cytokines, enzymes, and cell adhesion molecules, all of which can drive inflammatory and autoimmune disorders such as rheumatoid arthritis. The IKK complex plays the most important role in the signal cascade leading to NF-kappaB activation. Recently, inhibition of the interaction between NEMO (NF-kappaB essential modulator) and the catalytic subunits of IKK, especially IKKbeta, has received particular attention as a possible new therapeutic approach to treatment of inflammatory disorders, and several reports have shown the efficacy of cell permeable NEMO binding domain (NBD)-containing peptides in blocking the IKK/NF-kappaB pathway. In this article, we describe in detail the development and validation of two novel binding assays, a homogeneous time-resolved fluorescence (HTRF)-based assay and an enzyme-linked immunosorbent assay (ELISA)-based assay, suitable for the discovery of small molecules that inhibit IKKbeta-NEMO interaction. Using the HTRF-based assay, we screened approximately 15,000 compounds from our chemical library and eliminated false positive hits by the ELISA-based assay and IKK complex kinase assay. As a result, seven positive hit compounds that inhibit IKK complex activity through inhibition of IKKbeta-NEMO interaction were identified. These hit compounds may have a good potential in the treatment of inflammatory and autoimmune disorders such as rheumatoid arthritis.
